PROBLEM OF THE THERAPY USE AND RISK RATIO OF THE MEDICATION WHICH STIMULATE ERTHROPOESIS IN DIABETIC NEPHROPATHY
https://doi.org/10.24884/1561-6274-2010-14-3-32-36
Abstract
For more than 20 years to correct anemia in patients with chronic kidney disease (CKD) are used medications which stimulate erythropoesis (MSE). Currently in Russia there are multiple preparations of the MSE group: epoetin-α (epokrin, eralfon, Eprex), epoetin-β (Recormon), epoetin-ω (epomaks), darbepoetin-α (Aranesp), pegylated epoetin-β (Mircera ). Despite the fact that the study of the effectiveness of therapy MSE and its impact on the progression of CKD and cardiovascular disease was the subject of many studies, there is still no consensus regarding indications for treatment of MSE, the optimal therapeutic regimen and target hemoglobin levels.
About the Authors
I. Yu. Pchelin
Санкт-Петербургский государственный университет, г.Санкт-Петербург
Russian Federation
Russian Federation
A. N. Shishkin
Санкт-Петербургский государственный университет, г. Санкт-Петербург
Russian Federation
Russian Federation
L. P. Korobitsyn
ООО ”Протеиновый контур”, г. Санкт-Петербург
Russian Federation
Russian Federation
References
1. Elliott S, Pham E, Macdougall IC. Erythropoietins: A common mechanism of action. Exp Hematol 2008; 36: 1573-1584
2. Шестакова МВ, Дедов ИИ. Сахарный диабет и хроническая болезнь почек. ООО «Медицинское информационное агентство», М., 2009; 355-358
3. Kestenbaum B, Kimmel PL, Malozowski S et al. Reevaluating erythropoiesis-stimulating agents. N Engl J Med 2010; 362: 1742-1743
4. Bosman DR, Winkler AS, Marsden JT et al. Anaemia associated with erythropoietin deficiency occurs early in diabetic nephropathy. Diabetes Care 2001; 24: 495-499
5. Thomas MC, MacIsaac RJ, Tsalamandris C et al. Unrecognized Anemia in Patients with Diabetes: A cross-sectional survey. Diabetes Care 2003; 26: 1164-1169
6. McGill JB, Bell DSH. Anemia and the role of erythropoietin in diabetes. J Diabetes Complications 2006; 20: 262-272
7. McCullough PA, Bakris GL, Owen WF. Slowing the progression of diabetic nephropathy and its cardiovascular consequences. Am Heart J 2004; 48: 243-251
8. Najafian B, Mauer M. Progression of diabetic nephropathy in type 1 diabetic patients. Diabetes Res Clin Pract 2009; 83: 1-8
9. Hahr AJ, Molitch ME. Diabetes, Cardiovascular Risk and Nephropathy. Cardiol Clin 2010. In press
10. Conti AA, Minelli M, Gensini GF. Global management of high risk patients: Integrated primary cardiovascular prevention in diabetics. International Congress Series 2007; 1303: 10-20
11. Pfeffer MA, Burdmann EA, Chen CY et al. Baseline characteristics in the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT). Am J Kidney Dis 2009; 54: 59-69
12. Pfeffer MA, Burdmann EA, Chen CY et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 2009; 361: 2019-2032
13. Wright RJ, Kanagasundaram NS, Quinton R et al. Darbepoetin alfa and chronic kidney disease. N Engl J Med 2010; 362: 653-654
14. Marsden PA. Treatment of Anemia in Chronic Kidney Disease — Strategies Based on Evidence. N Engl J Med 2009; 361: 2089-2090
15. Drueke TB, Locatelli F, Clyne N et al. Normalization of Hemoglobin Level in Patients with Chronic Kidney Disease and Anemia. N Engl J Med 2006; 355: 2071-2084
16. Singh AK, Szczech L, Tang KL et al. Correction of Anemia with Epoetin Alfa in Chronic Kidney Disease. N Engl J Med 2006; 355: 2085-2098
17. Zoppini G, Targher G, Chonchol M et al. Anaemia, independent of chronic kidney disease, predicts all-cause and cardiovascular mortality in type 2 diabetic patients. Atherosclerosis 2010; 210: 575-580
18. Joss N, Patel R, Paterson K et al. Anaemia is common and predicts mortality in diabetic nephropathy. QJM 2007; 100: 641-647
19. Unger EF, Thompson AM, Blank MJ. Erythropoiesis-Stimulating Agents – Time for a reevaluation. N Engl J Med 2010; 362: 189-192
20. Vaziri ND, Zhou XJ. Potential mechanisms of adverse outcomes in trials of anemia correction with erythropoietin in chronic kidney disease. Nephrol Dial Transplant 2009; 24: 1082-1088
21. Konstantinopoulos PA, Karamouzis MV, Papavassiliou AG. Selective modulation of the erythropoietic and tissue-protective effects of erythropoietin: Time to reach the full therapeutic potential of erythropoietin. Biochim Biophys Acta 2007; 1776: 1-9
22. Ruifrok WT, Boer RA, Westenbrink BD et al. Erythropoietin in cardiac disease: New features of an old drug. Eur J Pharmacol 2008; 585: 270-277
23. Miura T, Miki T, Nishihara M et al. Molecular mechanisms of cardiomyocyte protection against ischemia/reperfusion injury by erythropoietin (EPO) receptor activation. J Mol Cell Cardiol 2006; 41: 1043-1044
24. Cooij MA, Groenendaal F, Kavelaars A et al. Neuroprotective properties and mechanisms of erythropoietin in ‘in vitro’ and ‘in vivo’ experimental models for hypoxia/ischemia. Brain Res Rev 2008; 59: 22-33
25. Pallet N, Bouvier N, Legendre C et al. Antiapoptotic properties of recombinant human erythropoietin protects against tubular cyclosporine toxicity. Pharmacol Res 2010; 61: 71-75
26. Wang W, Zhang J. Protective effect of erythropoietin against aristolochic acid-induced apoptosis in renal tubular epithelial cells. Eur J Pharmacol 2008; 588: 135-140
27. Chang YK, Choi DE, Na KR et al. Erythropoietin Attenuates Renal Injury in an Experimental Model of Rat Unilateral Ureteral Obstruction via Anti-Inflammatory and Anti-Apoptotic effects. J Urol 2009; 181: 1434-1443
28. Sekiguchi N, Inoguchi T, Kobayashi K et al. Erythropoietin attenuated high glucose-induced apoptosis in cultured human aortic endothelial cells. Biochem Biophys Res Commun 2005; 34: 218-222
29. Quin C, Xiao Y, Zhong Q et al. Anti-inflammatory effect of erythropoietin pretreatment on cardiomyocytes with hypoxia/reoxygenation injury and the possible mechanism. Chin J Traumatol 2008; 11: 352-358
30. Hirata A, Minamino T, Asanuma H et al. Erythropoietin Enhances Neovascularization of Ischemic Myocardium and Improves Left Ventricular Dysfunction After Myocardial Infarction in Dogs. J Am Coll Cardiol 2006; 48: 176-184
31. Lykissas MG, Sakellariou E, Vekris MD et al. Axonal regeneration stimulated by erythropoietin: An experimental study in rats. J Neurosci Methods 2007; 164: 107-115
32. Vaziri ND. Cardiovascular effects of erythropoietin and anemia correction. Curr Opin Nephrol and Hypertens 2001; 10: 633-637
33. Zhang Z, Barrett JD, Jamgotchian N et al. Recombinant human erythropoietin (rhEPO) stimulates gene transcription of renin angiotensin system and growth factor mRNAs in rat vascular smooth muscle cells [abstract]. J Investig Med 1996; 44: 91
34. Vaziri ND. Mechanism of erythropoietin-induced hypertension. Am J Kidney Dis 1999; 33: 821-828
35. Akimoto T, Kuzano E, Fujita N et al. Erythropoietin modulates angiotensin II-or noradrenaline-induced Ca2+ mobilization in cultured rat vascular smooth-muscle cells. Nephrol Dial Transplant 2001; 16: 491-499
36. Vogel V, Kramer HJ, Bдcker A et al. Effects of Erythropoietin on Endothelin-1 Synthesis and the Cellular Calcium Messenger System in Vascular Endothelial Cells. Am J Hypertens 1997; 10: 289-296
37. Eckardt KU. Erythropoietin and microvascular diabetic complications. Nephrol Dial Transplant 2009; 24: 388-390
38. Nagarajan S, Mansfield E, Hsieh S et al. Transplant reno-vascular stenoses associated with early erythropoietin use. Clin Transplant 2007; 21: 597-608
39. Fuste B, Seradell M, Escolar G et al. Erythropoietin triggers a signaling pathway in endothelial cells and increases the thrombogenicity of their extracellular matrices in vitro. Thromb Haemost 2002; 88: 687-685
40. Kahraman S, Yilmaz R, Kirkpantur A et al. Impact of rhEPO therapy initiation on soluble adhesion molecule levels in haemodialysis patients. Nephrology 2005; 10: 64-69
41. Гуревич КЯ, ред. Человеческий рекомбинантный эритропоэтин (Эпокрин) в лечении анемии (Практическое руководство). ИКФ «Фолиант», СПб., 2001; 45-46
42. Пчелин И. Ю, Шишкин А Н. Механизмы развития и клиническое значение анемии у пациентов с сахарным диабетом 1 и 2 типа. Вестн С.-Петерб ун-та Сер 11 2010; (2): 73-80
43. Kazory A, Ross EA. Anemia: The Point of Convergence or Divergence for Kidney Disease and Heart Failure? J Am Coll Cardiol 2009; 53: 639-647
44. Kleijn L, Boer RA, Voors AA. Should erythropoietin treatment in chronic heart failure be haemoglobin targeted? Eur J Heart Fail 2010; 12: 215-216
45. Goldsmith D, Covic A. Time to Reconsider Evidence for Anaemia Treatment (TREAT) = Essential Safety Arguments (ESA). Nephrol Dial Transplant 2010. In press
Review
For citations:
Pchelin I.Yu., Shishkin A.N., Korobitsyn L.P. PROBLEM OF THE THERAPY USE AND RISK RATIO OF THE MEDICATION WHICH STIMULATE ERTHROPOESIS IN DIABETIC NEPHROPATHY. Nephrology (Saint-Petersburg). 2010;14(3):32-36. (In Russ.) https://doi.org/10.24884/1561-6274-2010-14-3-32-36
Views:
396
Email this article 